Covington, Fenwick on $3B Japanese Pharma Deal
Japan's second-largest drugmaker, Astellas, is buying San Francisco-based Audentes for about $3 billion in cash.
December 04, 2019 at 01:41 PM
2 minute read
Covington & Burling and Fenwick & West have landed the lead roles on a $3 billion Japanese pharmaceutical deal.
Japan's second-largest drugmaker, Astellas Pharma Inc., has agreed to acquire San Francisco-based drugmaker Audentes Therapeutics Inc. for about $3 billion in cash. The transaction is expected to be completed in the first quarter of 2020, subject to regulatory approval, including U.S. antitrust clearance.
"By joining together with Audentes' talented team, we are establishing a leading position in the field of gene therapy with the goal of addressing the unmet needs of patients living with serious, rare diseases," said Astellas president and chief executive officer Kenji Yasukawa in a statement.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3'That's Disappointing': Only 11% of MDL Appointments Went to Attorneys of Color in 2023
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250